ArticleCell communication and signaling : CCS2026
Structural insights into the specificity of adaptor proteins Dok5 and Dok6 Docking to Trk receptors.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Specific neurotrophic signaling by Trk receptors relies on the selective recruitment of downstream adaptors such as Dok5 and Dok6, yet the structural basis underlying this selectivity has remained unresolved. Here, we elucidate the principles governing Trk-Dok specificity by integrating structural prediction with biochemical validation. Comparative analysis of AlphaFold3-predicted complexes reveals that the intracellular domains of Trk dimers exhibit model-based interpretation, matching the distinct pocket architectures of Dok5 and Dok6. Ligand-induced phosphorylation exposes critical Trk tyrosine residues, enabling high-affinity engagement by adaptor PTB domains. We identify a conserved interaction hotspot centered on Trk Tyr515/516 and Dok Tyr187 that anchors this recognition. Crucially, co-immunoprecipitation assays validate that the C-terminal domains of Dok proteins exert modulatory control via steric hindrance, a finding consistent with our structural model. Collectively, our study establishes spatial complementarity and phosphorylation-dependent exposure of docking sites as key principles governing Trk-Dok signaling specificity, providing new structural insights into neurotrophin signaling and its potential therapeutic modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.